Lantern Pharma

#Oncology #AI-Driven Drug Development #Central Nervous System

Clinical-stage oncology company that uses its AI and machine-learning RADR platform to rescue, reposition and accelerate the development of existing and previously abandoned drug candidates, with a pipeline of DNA-damage-response therapeutics and a separate CNS-focused joint venture.

Company Info

Sector:Biotechnology

Headquarters:Dallas, Texas, USA

Founded:2013

Website:www.lanternpharma.com/

Upcoming Milestones & Key Dates

2027-03

Regulatory

Deadline to regain compliance with Nasdaq's minimum market value of listed securities standard

Clinical Development Pipeline

LP-300

Target: DNA damage response

Non-smoker non-small cell lung cancer adenocarcinoma (combination therapy)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LP-184

Target: DNA damage response (PTGR1-activated)

Advanced or metastatic solid tumors and CNS cancers including glioblastoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LP-284

Target: DNA damage response (PTGR1-activated)

Non-Hodgkin's lymphomas including mantle cell and double-hit lymphoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

STAR-001

Target: Not publicly disclosed

Glioblastoma, brain metastases and rare pediatric CNS tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Panna Sharma

President, Chief Executive Officer and Director

David R. Margrave

Chief Financial Officer and Secretary

Careers & Job Openings

Biopharma Software Engineer

Computational Biology / Software

Dallas, Texas, USA

Apply Now →